Clinical Trial Highlights

• ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Neither Reduces CV Events Nor Increases Cancers in Diabetic Patients
• Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss through 4 Years
• DiaPep277® Shows Promise as a Therapeutic Strategy for Type 1 Diabetes
• Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
• 12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus
• Insulin Degludec is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents
• Dapagliflozin Does Not Impact Renal Function in Patients with Type 2 Diabetes
• Population-Based Screening for Type 2 Diabetes: The ADDITION-Cambridge Trial